Adicet Bio, Inc.
corporate_fare Company Profile
Adicet Bio, Inc. (NASDAQ:ACET) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 18 items for ACET at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 8/10. Across its 18 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for ACET spans 10-Q, 8-K, 4, SCHEDULE 13D/A.
Recent high-impact activity:
- Adicet 10-Q Adds Going-Concern Warning Despite $100.9M Cash Into 2H 2027
- Adicet Q3: $100.9M Cash Into 2H 2027, Pivotal Lupus Study Starting, FDA Meeting in 4Q
- Adicet Bio Reports Positive Phase 1 Data for Prula-cel in Lupus: 50% CRR, 54% DORIS Remission
- Adicet's Prula-cel Shows 50% Complete Renal Response in Lupus Nephritis, Pivotal Study Planned
- Adicet Bio Completes Last Patient Visit for prula-cel SLE Study; Topline Data Due September 2026
Financial Snapshot
Short Interest & Short Volume
2.57 days to coverFINRA reported short interest of 459,550 shares in ACET as of the October 30, 2026 settlement, a 11.9% decrease from the prior period — about 2.6 days to cover at its recent average daily volume. On November 20, 2026, 22.3% of ACET volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.